Free Trial
→ How to claim a stake in SpaceX before the June 12 IPO (From Brownstone Research) (Ad)tc pixel Free TLM Stock Alerts

Talisman Metals (TLM) Competitors

GBX 7 -0.25 (-3.45%)
As of 04:03 AM Eastern
Compare

TLM vs. FAB, RLM, NSCI, CIZ, and GENF

Should you buy Talisman Metals stock or one of its competitors? MarketBeat compares Talisman Metals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Talisman Metals include Fusion Antibodies (FAB), Realm Therapeutics (RLM), NetScientific (NSCI), Cizzle Biotechnology (CIZ), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.

How does Talisman Metals compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Talisman Metals (LON:TLM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Talisman Metals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Talisman Metals' return on equity of -32.71% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Talisman Metals N/A -32.71%3.70%

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Talisman Metals'average media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Talisman Metals Neutral

Fusion Antibodies has a beta of 1.215, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Talisman Metals has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Talisman Metals has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.79-£4.10M-£1.50N/A
Talisman MetalsN/AN/A-£1.35M-£1.32N/A

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 1.4% of Talisman Metals shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by insiders. Comparatively, 95.2% of Talisman Metals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Talisman Metals beats Fusion Antibodies on 7 of the 10 factors compared between the two stocks.

How does Talisman Metals compare to Realm Therapeutics?

Realm Therapeutics (LON:RLM) and Talisman Metals (LON:TLM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Realm Therapeutics' return on equity of 0.00% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
Realm TherapeuticsN/A N/A N/A
Talisman Metals N/A -32.71%3.70%

1.4% of Talisman Metals shares are held by institutional investors. 95.2% of Talisman Metals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Realm Therapeutics' average media sentiment score of 0.00 equaled Talisman Metals'average media sentiment score.

Company Overall Sentiment
Realm Therapeutics Neutral
Talisman Metals Neutral

Realm Therapeutics has higher revenue and earnings than Talisman Metals. Talisman Metals is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Realm Therapeutics£501.92K0.00N/A-£17.50N/A
Talisman MetalsN/AN/A-£1.35M-£1.32N/A

Summary

Talisman Metals beats Realm Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Talisman Metals compare to NetScientific?

Talisman Metals (LON:TLM) and NetScientific (LON:NSCI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

1.4% of Talisman Metals shares are owned by institutional investors. Comparatively, 14.7% of NetScientific shares are owned by institutional investors. 95.2% of Talisman Metals shares are owned by insiders. Comparatively, 42.4% of NetScientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Talisman Metals has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, NetScientific has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

Talisman Metals has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
Talisman MetalsN/A -32.71% 3.70%
NetScientific -182.91%-13.70%-9.42%

In the previous week, Talisman Metals' average media sentiment score of 0.00 equaled NetScientific'saverage media sentiment score.

Company Overall Sentiment
Talisman Metals Neutral
NetScientific Neutral

Talisman Metals has higher earnings, but lower revenue than NetScientific. Talisman Metals is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talisman MetalsN/AN/A-£1.35M-£1.32N/A
NetScientific£1.45M0.00-£2.64M-£0.11N/A

Summary

Talisman Metals and NetScientific tied by winning 5 of the 10 factors compared between the two stocks.

How does Talisman Metals compare to Cizzle Biotechnology?

Cizzle Biotechnology (LON:CIZ) and Talisman Metals (LON:TLM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Cizzle Biotechnology's average media sentiment score of 0.00 equaled Talisman Metals'average media sentiment score.

Company Overall Sentiment
Cizzle Biotechnology Neutral
Talisman Metals Neutral

Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cizzle BiotechnologyN/AN/A-£2.81K-£0.17N/A
Talisman MetalsN/AN/A-£1.35M-£1.32N/A

Cizzle Biotechnology's return on equity of 104.99% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cizzle BiotechnologyN/A 104.99% -31.72%
Talisman Metals N/A -32.71%3.70%

Cizzle Biotechnology has a beta of 0.068073176, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Talisman Metals has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

0.0% of Cizzle Biotechnology shares are owned by institutional investors. Comparatively, 1.4% of Talisman Metals shares are owned by institutional investors. 72.2% of Cizzle Biotechnology shares are owned by insiders. Comparatively, 95.2% of Talisman Metals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Talisman Metals beats Cizzle Biotechnology on 5 of the 8 factors compared between the two stocks.

How does Talisman Metals compare to Genflow Biosciences?

Genflow Biosciences (LON:GENF) and Talisman Metals (LON:TLM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Genflow Biosciences has a net margin of 840.76% compared to Talisman Metals' net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Talisman Metals N/A -32.71%3.70%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Talisman MetalsN/AN/A-£1.35M-£1.32N/A

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 1.4% of Talisman Metals shares are held by institutional investors. 47.5% of Genflow Biosciences shares are held by insiders. Comparatively, 95.2% of Talisman Metals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genflow Biosciences has a beta of 2.108, indicating that its stock price is 111% more volatile than the broader market. Comparatively, Talisman Metals has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Talisman Metals'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Talisman Metals Neutral

Summary

Talisman Metals beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

Get Talisman Metals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLM vs. The Competition

Export
MetricTalisman MetalsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.49M£464.34M£6.44B£2.80B
Dividend Yield0.83%3.86%2.75%6.08%
P/E Ratio-5.303.3921.48365.44
Price / SalesN/A7,036.56618.7787,845.66
Price / Cash1.0013.1343.1327.89
Price / Book2.9085.5410.547.76
Net Income-£1.35M-£96.07M£3.56B£5.89B
7 Day Performance-5.91%1.14%3.27%1.91%
1 Month Performance-6.67%3.02%4.72%4.58%
1 Year PerformanceN/A90.18%38.14%69.99%

Talisman Metals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLM
Talisman Metals
N/AGBX 7
-3.4%		N/AN/A£4.49MN/AN/A5
FAB
Fusion Antibodies
N/AGBX 12.64
-4.6%		N/A+91.8%£15.80M£1.60MN/A48
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
CIZ
Cizzle Biotechnology
N/AGBX 3.05
+5.2%		N/A+68.7%£12.09MN/AN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TLM) was last updated on 5/28/2026 by MarketBeat.com Staff.
From Our Partners
The math on the SpaceX IPO is broken
SpaceX is expected to go public at a $1.75 trillion valuation. For investors to see a 10x return, the company ...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
They're not telling you how bad this could get
Valuations are stretched to levels seen only a handful of times in the last hundred years — yet most retiremen...
Parkview Capital Group | Sponsoredtc pixel
Hidden on Tesla's filing: A $12 billion "super startup"
Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...
Banyan Hill Publishing | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
How daily 'stock bets' hit 87% of the time
A daily trading system claims an 87% win rate on short-term stock plays - and it runs just one hour a day, fro...
Trade To Close | Sponsoredtc pixel